US-based Curi Bio, the leader in delivering human-relevant functional data for drug discovery and development, has announced the formal establishment of Curi Bio Co., Ltd., a wholly-owned subsidiary, following the full acquisition of Quvit Bio of South Korea.
The new subsidiary will serve as Curi Bio’s commercial and operational hub in the Asia-Pacific (APAC) market, significantly expanding its direct presence and scientific capabilities to serve its growing customer base.
"Curi Bio Co., Ltd. represents a day-1 ready sales, R&D, and operational hub, allowing us to directly serve the APAC market. We can now offer localised technical and sales support for our existing customer base across South Korea, Japan, and China while lowering the access barrier to Curi’s industry-leading NAM technology for all drug developers in the region. In addition, the establishment of a local operations hub ensures that we can deliver our cells, media, hardware, and consumables products with minimal delays due to international logistics. This signals our commitment to providing human-relevant preclinical data to guide business decisions that speed next-generation medicines to market across the globe”, said Dr Nicholas Geisse, CEO of Curi Bio.
The strategic move includes the acquisition of Quvit Bio’s assets and team, bringing immediate expertise in regional sales, business development, hardware and software engineering, and life science tools. Curi Bio Co., Ltd. is a full-service hub, going beyond business development and immediately providing technical and sales support to APAC customers across Curi’s product and services portfolio.
